Sunstone says Big Pharma Phase III trial mix signals rising M&A interest in psychiatry
XLV•Big Pharma Concentration Index flags psychiatry and autoimmune disease
Sunstone says its Big Pharma Concentration Index uses 1 as neutral representation, with changes above 0.20 flagged as potentially significant.
The psychiatry index rose to 1.26 from 0.28, which Sunstone says signals a sharp increase in large-cap drugmaker engagement.
The autoimmune disease index increased to 1.85 from 1.53, indicating already elevated interest is still building.
Sunstone’s Phase III trial analysis points to changing Big Pharma interest
Sunstone says its analysis of nearly 50,000 Phase III trials is intended to gauge shifts in Big Pharma partnering or M&A appetite.
The method compares sponsors with market caps above $10 billion versus others, split between recruiting trials and post-enrollment trials awaiting data.
